ProQR Therapeutics N.V.
PRQR Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- ProQR Therapeutics N.V. had $17.9M of revenue in fiscal 2025, down 12.3% on the year before.
- Its operating margin was −273.1%, down 112.0 pts: of every 100 in sales, about −273 is left after running the business.
- ProQR Therapeutics N.V. lost $47.6M in fiscal 2025.
- Free cash flow was −$60.7M in fiscal 2025, −338.3% of revenue.
- ProQR Therapeutics N.V. has $103M more cash than debt.
Market cap
—
P/E
—
Revenue
$17.9M
Net income
−$47.6M
Free cash flow
−$60.7M
Operating margin
−273.1%
ProQR Therapeutics N.V. in 30 seconds · fiscal 2025
Are sales growing?
−12.3%
No. Sales fell 12.3% last year.
Does it make a profit?
−265.2%
No. It lost money last year.
Does profit turn into cash?
−338.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
What ProQR Therapeutics N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 12, 2026
- Legal name
- ProQR Therapeutics N.V.
- CIK
- 0001612940
ProQR Therapeutics N.V. · PRQR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.6M | $3.8M | $7.0M | $20.5M | $17.9M |
| Revenue growth | — | 135.9% | 86.5% | 190.3% | −12.3% |
| Operating margin | −4,225.3% | −1,813.0% | −489.1% | −161.2% | −273.1% |
| Net income | −$71.8M | −$67.7M | −$30.4M | −$30.0M | −$47.6M |
| Net margin | −4,486.1% | −1,792.5% | −431.7% | −146.9% | −265.2% |
| Diluted EPS | −$1.12 | −$0.95 | −$0.38 | −$0.35 | −$0.45 |
| Cash | |||||
| Cash from operations | −$30.8M | −$72.0M | $23.3M | −$39.4M | −$59.5M |
| Capital expenditure | $0.6M | $0.7M | $1.5M | $1.5M | $1.2M |
| Free cash flow | −$31.3M | −$72.7M | $21.8M | −$40.9M | −$60.7M |
| FCF margin | −1,956.9% | −1,925.9% | 309.7% | −200.0% | −338.3% |
| Share count change | 28.2% | 11.6% | 13.1% | 6.3% | 22.4% |
| Debt and strength | |||||
| Cash and short-term investments | $212M | $101M | $131M | $155M | $109M |
| Debt incl. finance leases | $49.9M | $7.2M | $4.7M | $4.8M | $5.7M |
| Shareholders' equity | $129M | $71.5M | $45.7M | $92.0M | $58.0M |
| Current ratio | 6.9x | 7.4x | 3.5x | 4.0x | 3.1x |
| Interest coverage | −16.8x | −12.7x | −26.5x | −28.3x | −46.8x |
| Returns and quality | |||||
| Return on equity | −72.2% | −67.6% | −51.9% | −43.6% | −63.4% |
| Return on tangible equity | −55.7% | −94.7% | −66.5% | −32.6% | −82.0% |
| Piotroski F-score | 2 | 3 | 5 | 4 | 1 |
| Altman Z'' | −0.5 | −3.9 | −6.4 | −3.9 | −11.2 |
Insiders bought, 12 months
$1.3M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ProQR Therapeutics N.V. · PRQR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001612940). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.